Affected market: Biopharmaceuticals
No. ME/2433/06
On the basis of the information available to it, the OFT has decided that the anticipated acquisition by AstraZeneca UK Limited of Cambridge Antibody Technology plc does not qualify for investigation under the mergers provisions of the Enterprise Act 2002 (the Act), because neither the UK turnover test nor the share of supply test in section 23 of the Act is met. A relevant merger situation has, therefore, not been created.
This feature requires Javascript and Cookies to be enabled on your browser
Register for email alerts or amend your existing account details here.